

## ORIGINAL ARTICLE

# Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop

S. COINTE,\*† C. JUDICONE,†‡ S. ROBERT,\* M. J. MOOBERRY,§ P. PONCELET,‡ M. WAUBEN,¶ R. NIEUWLAND,\*\* N. S. KEY,§ F. DIGNAT-GEORGE\*† and R. LACROIX\*†

\*VRCM, UMR-S1076, Aix-Marseille Université, INSERM, UFR de Pharmacie; †Hematology and Vascular Biology Department, CHU La Conception, Assistance Publique-Hôpitaux de Marseille; ‡R and T Department, BioCytex, Marseille, France; §Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; ¶Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht; and \*\*Laboratory of Experimental Clinical Chemistry, Academic Medical Center, Amsterdam, the Netherlands

**To cite this article:** Cointe S, Judicone C, Robert S, Mooberry MJ, Poncelet P, Wauben M, Nieuwland R, Key NS, Dignat-George F, Lacroix R. Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. *J Thromb Haemost* 2017; **15**: 187–93.

See also Zwicker JI. Scattering the spotlight on microparticles. This issue, pp 185–6.

## Essentials

- The clinical enumeration of microparticles (MPs) is hampered by a lack of standardization.
- A new strategy to standardize MP counts by flow cytometry was evaluated in a multicenter study.
- No difference was found between instruments using forward or side scatter as the trigger parameter.
- This study demonstrated that beads can be used as a standardization tool for MPs.

## Click to hear the ISTH Academy's webinar on microvesicles

**Summary.** *Background:* Microparticles (MPs) are extracellular vesicles resulting from the budding of cellular membranes that have a high potential as emergent biomarkers; however, their clinical relevance is hampered by methodological enumeration concerns and a lack of standardization. Flow cytometry (FCM) remains the most commonly used technique with the best capability to determine the cellular origin of single MPs. However,

instruments behave variably depending on which scatter parameter (forward (FSC) or side scatter (SSC)) provides the best resolution to discriminate submicron particles. To overcome this problem, a new approach, based on two sets of selected beads adapted to FSC or SSC-optimized instruments, was recently proposed to reproducibly enumerate platelet-derived MP counts among instruments with different optical systems. *Objective:* The objective was to evaluate this strategy in an international workshop that included 44 laboratories accounting for 52 cytometers of 14 types. *Methods/Results:* Using resolution capability and background noise level as criteria to qualify the instruments, the standardization strategy proved to be compatible with 85% (44/52) of instruments. All instruments correctly ranked the platelet MP (PMP) levels of two platelet-free plasma samples. The inter-laboratory variability of PMP counts was 37% and 28% for each sample. No difference was found between instruments using forward or side-scattered light as the relative sizing parameter. *Conclusions:* Despite remaining limitations, this study is the first to demonstrate a real potential of bead-based strategies for standardization of MP enumeration across different FCM platforms. Additional standardization efforts are still mandatory to evaluate MPs' clinical relevance at a multicenter level.

**Keywords:** cell-derived microparticles; extracellular vesicles; flow cytometry; multicenter study; standardization.

Correspondence: Romaric Lacroix, VRCM, UMR-1076, 27 Bd Jean Moulin, 13005 Marseille, France.

Tel.: +33 49 138 5600; fax: +33 49 138 5602.

E-mail: romaric.lacroix@univ-amu.fr

Received 11 March 2016

Manuscript handled by: P. H. Reitsma

Final decision: F. R. Rosendaal, 26 August 2016

## Introduction

Among extracellular vesicles, microparticles (MPs) are submicron-sized vesicles released by blebbing from cell

membranes in response to activation or apoptosis. MPs originate from blood and vascular cells, and plasma levels are elevated in a variety of prothrombotic and inflammatory disorders, cardiovascular diseases, autoimmune disorders, infectious diseases and malignancies [1].

Although MP counts may provide useful diagnostic/prognostic information, assessment of their pathophysiological relevance in multicenter studies is hampered by methodological concerns and a lack of standardization. Among the various methodologies available to measure MPs in biological samples, flow cytometry (FCM) remains the most commonly used technique with the highest potential to determine the cellular origin of single MPs [2]. Over the past few years, significant improvements have been made in the sensitivity of flow cytometers to detect vesicles of smaller size, which have confirmed this methodology as the most promising for routine enumeration of MP subsets [3–5].

Six years ago, a first collaborative workshop defined the inter-laboratory reproducibility of platelet MP (PMP) counts using FCM [6]. The standardization strategy was based on the forward light scatter (FSC) signal of size-calibrated latex beads to set a common MP window of analysis [7]. However, the variety of optical designs among flow cytometer (FCMr) subtypes impeded a universal standardization strategy for PMP enumeration. Because a better resolution and a more homogeneous response of instruments was observed in a subgroup of FCMrs using the light scatter signal measured at 90° (side scatter, SSC) rather than FSC, a new set of beads was selected to better suit the design of these SSC-oriented instruments [8]. Correspondence between the two sets of beads was accurately determined so that similar PMP counts were obtained on both types of FCMrs. Thus, a new standardization strategy is proposed based on the use of two types of beads, each adapted to instruments of different optical design. Based on this strategy, the International Society on Thrombosis and Haemostasis (ISTH) Vascular Biology Standardization Subcommittee organized an additional workshop to evaluate the inter-instrument reproducibility of PMP counts among different platforms.

## Materials and methods

### Study design

The study was conducted in two stages over a 2-year period. The first stage was aimed at qualifying the instruments for the standardization strategy according to required performance levels of scatter resolution and background noise. This step led to acceptance or rejection of the tested instrument(s). In the second stage, the inter-instrument reproducibility of three different platelet-free plasma (PFP) samples, prepared by the core laboratory and

featuring defined levels of PMP subsets, was evaluated using common reagents and the standardized protocol.

### Cytometers

The study included 44 laboratories from 17 different countries, accounting for 52 registered cytometers. The tested instruments included 11 FACSCanto (I/II), six FACSCalibur, two FACSVerse, five FACSARIA (I/II), four LSRII, three LSR Fortessa, one Influx and two Accuri C6 from Becton-Dickinson (BD, Franklin Lakes, NJ, USA), one EPICS XL, two FC500 and 12 Gallios/Navios from Beckman-Coulter (BC, Miami, FL, USA), one Apogee A50 micro (Apogee System, Hemel Hempstead, Hertfordshire, UK), one Guava EasyCyte (Millipore, Hayward, CA, USA) and one Stratifiedigm S1000 EXi (Stratifiedigm, San Jose, CA, USA).

### Standardization beads

Megamix-Plus FSC or SSC beads were provided by BioCytex (Marseille, France) to the core laboratory, which distributed them to participants according to their instrument's characteristics. Megamix-Plus SSC is a ready-to-use mix of fluorescent polystyrene beads of various diameters (0.16, 0.20, 0.24 and 0.5 µm) dedicated to flow cytometers using SSC as the best resolving size-related parameter. Megamix-Plus FSC is a mix of fluorescent polystyrene beads of various diameters (0.1, 0.3, 0.5 and 0.9 µm) dedicated to FCMrs using FSC as the best resolving size-related parameter. The intrinsic numerical ratio of 2 : 1 from the 0.3 to 0.5 µm beads facilitates fine-tuning of the FSC threshold [3]. According to the instrument characteristics, standardization beads were tested as follows. Megamix-Plus FSC: Gallios, Navios, FC500, Epics XL and Guava. Megamix-Plus SSC: FACSARIA (I/II), LSR II (+/- Fortessa), FACSCanto (I/II), FACSVerse, FACSCalibur, Accuri C6. Megamix-Plus FSC and Megamix-Plus SSC: Influx, Apogee A50 and Stratifiedigm.

### Flow cytometry reagents

The common flow cytometry reagents for PMP staining were annexinV-FITC (fluorescein) (Tau Technologies, Kattendijke, the Netherlands) and its associated binding buffer, and CD41-PE (phycoerythrin; clone PL2-49) and its concentration-matched isotype control IgG1-PE (clone 2DNP-2H11/2H12), both from BioCytex. Counting beads (3 µm, MP-count beads, prototype version) were from BioCytex.

### Platelet-free plasma preparation

Platelet-free plasma (PFP) was prepared at the core laboratory. Briefly, blood from healthy donors, who signed an informed consent form, was collected with a 21-gauge

needle in 0.129 M citrated tubes after discarding the first 2 mL. Platelet-free plasma was prepared according to a published protocol using two successive centrifugations, each of 15 min at 2500 g [9,10] with the following modifications. Sample A was prepared after agitation of the blood tubes at room temperature on a rotating wheel for 2 h. Sample C was prepared after a 2-h delay without agitation. Samples A and C were prepared from a pool of 10 donors, whereas sample B was from a unique donor. Aliquots (200  $\mu$ L) of PFP were stored at  $-80^{\circ}\text{C}$  until use (less than 6 months). Inter-aliquot variability of PFP samples was measured on a single instrument (Gallios) by the core laboratory over a 2-month period, yielding values with CVs of 14%, 8% and 24% ( $n = 18$ ) for samples A, B and C, respectively. The variability of a triplicate measurement of one aliquot was also found to be acceptable, resulting in CVs of 10%, 8% and 16% ( $n = 6$ ). Given the high variability of PMP counts on sample C, results with this sample were retrospectively excluded from the study. The preparation of this sample as a mixture of plasma from different blood groups may have generated MP aggregates with an impact on MP count reproducibility.

#### *Instrument qualification*

Instrument qualification to enable the proposed strategy was based on two criteria [8]. First, a sufficient resolution was required to resolve small beads whose size depends on the selected scatter parameter (0.3 and 0.5  $\mu\text{m}$  for FSC and 0.16 and 0.2  $\mu\text{m}$  for SSC). This was attested by a scatter sensitivity index  $> 3$  ( $\text{SSI} = (\text{Median bead A} - \text{Median bead B}) / (\text{SD bead A} + \text{SD bead B})$ ) [11]. The second criterion was based on a background noise ratio (BNR), which was defined as the ratio between the number of events per second measured in the protocol settings and the maximal number of events per second acceptable by the instrument without significant abort rate (FACSCanto I/II = 4000, FACSCalibur = 2000, FACSaria I/II = 4000, LSRII (+/- Fortessa) = 4000, FACSVerse = 4000, Apogee A50 = 2000, Stratedigm = 4000, Gallios/Navios = 5000, Influx = 15 000, defined according to both instrument specifications and core laboratory validation). BNR was evaluated on filtered distilled water and should be lower than one in order to avoid impeding the instrument's electronic system.

#### *Protocol setting*

The standardization protocols were set according to the manufacturer's instructions for SSC and FSC Megamix beads. For FSC-optimized instruments, the MP analysis region was defined as follows: (i) the upper boundary was determined by the edge of the 0.9- $\mu\text{m}$  bead cloud, and (ii) the lower boundary was defined by the threshold on FSC that allowed inclusion of 50% of the 0.3- $\mu\text{m}$  beads in the analysis. A range of 48% to 52% was considered

acceptable [3]. For SSC-optimized instruments, the upper boundary of the MP analysis region was determined by the end of the 0.5- $\mu\text{m}$  bead peak (e.g. 99th percentile). The lower boundary was set according to the product insert following the formula: Low SSC-H level = Median 0.16  $\mu\text{m}$  beads +  $(0.3 \times (\text{Median } 0.20 \mu\text{m beads} - \text{Median } 0.16 \mu\text{m beads}))$  [8]. The MP protocol settings were optimized as follows. (i) Scatter settings were optimized recording PEAK (= HEIGHT) signals. (ii) Low flow rate was selected and acquisition time was optimized according to the MP count beads (60 s when the total number of MP count beads in 1 min ranged from 500 to 2000 or 120 s if MP count beads were  $< 500$ ). (iii) Fluorescence settings were optimized by setting FL1 and FL2 PMT voltages to reach predefined target values (median intensities) for single fluorescence positive beads ('Fluo-Setting-Beads' (FSB), designed by BioCytex for this exercise). Briefly, blank beads as well as high-intensity FITC-labelled and PE-labelled beads were mixed extemporaneously, and staining reagents (AnnV-FITC + CD41-PE) were added at the same final concentrations as in plasma samples, thus providing a comparable level of non-specific fluorescence background. (iv) Compensation settings were set up using single fluorescence labelling of PFP samples. (v) Positive and negative region boundaries were defined using concentration-matched isotype control and AnnV-FITC in filtered PBS without calcium so that  $< 0.1\%$  of events were included in the positive gates. Detailed instructions for optimization of the MP protocol setting can be found in data S1.

#### *PMP counting experiments*

Three PMP counting experiments were performed for each PFP sample operated in independent series. Before running each series of samples, standardized scatter settings were checked with Megamix-Plus and fluorescence target channels assessed with Fluo-Setting-Beads. A total of 30  $\mu\text{L}$  of PFP were incubated for 20 min with 10  $\mu\text{L}$  of AnnV-FITC and 5  $\mu\text{L}$  of CD41-PE, and then diluted in 1 mL of Binding Buffer. A negative control was performed for each PFP by incubating 30  $\mu\text{L}$  of PFP with 10  $\mu\text{L}$  of AnnV-FITC and 5  $\mu\text{L}$  of IgG1-PE, and diluting the sample in PBS without calcium. In order to derive absolute PMP counts per  $\mu\text{L}$  of plasma, 30  $\mu\text{L}$  of counting beads (MP-count beads) were added before running the samples. PMP concentration in plasma was calculated according to the formula:  $\text{events}/\mu\text{L} = \text{double positive events} \times \text{counting bead concentration}/\text{number of counting beads}$ . Non-specific events/ $\mu\text{L}$  in the control tube were subtracted from the PMP counts.

#### *File transfer and re-analysis*

All electronic raw data (listmode) files corresponding to instrument qualification, protocol setting and PFP analysis were sent to the core laboratory in fcs (flow cytometry

standard format) 2.0 or fcs 3.0. Files were re-analyzed by the core laboratory using the same software (Kaluza v1.2 software, Beckman Coulter). In the event of irreversible discrepancies with the protocol instructions, data were not accepted for final analysis.

### Statistical analysis

All statistical analyses were performed using GraphPad Prism software v.5.0 (GraphPad Software, San Diego, CA, USA). Each PFP was analyzed in triplicate and the mean of this triplicate (xi) was considered for further analysis. The robust mean ( $X^*$ ) and robust standard deviation ( $SD^*$ ) of these data were calculated, taking into account only the results from cytometers with values between median  $\pm$  SD [12]. The Mann–Whitney test was used to compare instrument families. A result was considered significant if  $P < 0.05$ .

## Results

### Instrument qualification

Instruments were qualified for the standardization strategy according to their resolution capability and low background noise. As illustrated in Table 1, with the exception of two Accuri C6 and one FACSAria, most instruments using exclusively the SSC strategy showed an  $SSI > 3$ , indicating that the resolution was sufficient to enable the proposed strategy. Among these instruments,

LSRII ( $\pm$  LSRII Fortessa) showed the best resolution ( $SSI = 7.9 \pm 1.3$ ,  $n = 7$ ). All SSC-FCMs (except a FACSCalibur) showed a background noise that was acceptable in the standardization protocol settings. Overall, combining both criteria, 87% of the instruments that used SSC as the preferred parameter were found to be qualified. Regarding instruments that used FSC, only the last generation of FCMr (Gallios/Navios, Stratedigm and BD Influx) showed an  $SSI > 3$  (Table 1). Among these instruments, BD Influx and Apogee A50 showed the best resolution ( $SSI = 11.3$ ,  $n = 2$ ). Regarding background noise, five (of 12) Gallios/Navios showed a  $BNR > 1$ . This noise proved to be of optical origin and was reversible by externally cleaning the flow cell of dust deposits. Therefore, these instruments were incorporated into the second stage of the study. The qualification step resulted in a 75% qualification rate for FSC-optimized instruments. Finally, the standardization strategy proved to be compatible with 44/52 instruments (85%).

### Inter-instrument variability

In the second stage of the protocol, participating laboratories with qualified instruments enumerated PMPs on three PFP samples prepared by the core laboratory. Because of the 1-year delay between the two stages of the workshop, it was necessary to check SSI and BNR of the instruments again before analyzing the samples. The qualification criteria were the same as in the first stage. As a result, with the exception of two Navios with


**Table 1** Instrument qualification according to resolution and background noise

	Instrument type	SSI mean [min-max]	BNR mean [min-max]	Qualified instruments	
SSC instruments	Accuri C6	0	ND	0/2	
	Apogee A50 <sup>a</sup>	7.7	0.03	1/1	
	FACSAria	5.2 [2.8–7.1]	0.07 [0–0.22]	4/5	
	FACSCalibur	4.6 [3–6.5]	0.58 [0–2.59]	5/6	
	FACSCanto	4.5 [3.4–7]	0.07 [0.01–0.2]	11/11	
	FACSVerse	7.1 [7–7.3]	0.12 [0.06–0.19]	2/2	
	Influx <sup>a</sup>	2.4	0.43	0/1	
	LSR Fortessa	8 [7.2–9.1]	0.02 [0.02–0.05]	3/3	
	LSR II	7.9 [5.7–10]	0.02 [0–0.03]	4/4	
	Stratedigm <sup>a</sup>	4.3	0.02	1/1	
	FSC instruments	Apogee A50 <sup>a</sup>	11.3	0	1/1
		Epics XL	0	ND	0/1
FC500		0	ND	0/2	
Guava		0	ND	0/2	
Influx <sup>a</sup>		11.3	0.01	1/1	
Navios/Gallios		5.6 [2.8–7.6]	1.53 [0–6.2] (0.03) <sup>b</sup>	7/12 (12/12) <sup>b</sup>	
Stratedigm <sup>a</sup>		4	1	1/1	
Total				39/52 (44/52) <sup>b</sup>	

<sup>a</sup>Instruments tested both in side scatter (SSC) and forward scatter (FSC). <sup>b</sup>Results after flow cell wash. Sensitivity index (SSI) = (Median bead A – Median bead B)/(SD bead A + SD bead B) where bead A = 0.2  $\mu$ m and bead B = 0.16  $\mu$ m for SSC FCMs, and bead A = 0.5  $\mu$ m and bead B = 0.3  $\mu$ m for FSC FCMs.  $SSI > 3$  was required to be compatible with the standardization strategy. Background noise ratio (BNR) is the ratio between the number of events per second measured in the protocol settings and the instrument-specific maximal number of events per second keeping abort rate at a low level (FACSCanto I/II = 4000, FACSCalibur = 2000, FACSAria I/II = 4000, LSRII ( $\pm$ Fortessa) = 4000, FACSVerse = 4000, Apogee A50 = 2000, Stratedigm = 4000, Gallios/Navios = 5000, Influx = 15 000, defined according to both instrument specifications and core laboratory validation). ND, not determined.

significant background noise, all instruments re-qualified. The standardized protocol was set up optimizing the scatter settings, flow rate, fluorescence and compensation settings, and region boundaries as detailed in Methods. After analysis of the FCM raw data files by the core laboratory, data from three instruments were rejected due to irreversible discrepancies with the protocol instructions. Also, plasma sample C was excluded from analysis because of its inherent heterogeneity leading to high PMP count CVs at the core laboratory (Fig. S1). Each PFP was analyzed in triplicate. The mean CV for each triplicate of the validated PMP counts was 15% and 12% for samples A and B, respectively. Individual results showing a triplicate CV > 50%, suggestive of a manipulator-dependent bias, were not considered valid (three instruments for sample A and no instrument for sample B). Finally, among the 32 results received by the core laboratory for samples A and B, 81% and 91% were considered valid, respectively.

As shown in Fig. 1, all instruments with validated results for the two samples ( $n = 26$ ) correctly discriminated the two PMP levels. The inter-instrument variability of the ratio between samples A and B was 30.2% and was not significantly different between the instruments using SSC or FSC as the preferred scatter parameter ( $35.1 \pm 4.9$  vs.  $39.3 \pm 14.3$ , respectively,  $P = 0.7$ ). As illustrated in Fig. 2(A) for sample A, 58% of instruments provided comparable PMP counts within a restricted range of values (robust mean  $\pm$  robust SD). This result was better with sample B (69%, Fig. 2B). Fifteen out of 26 instruments (58%) gave results within the robust mean  $\pm$  robust SD range. However, some individual instruments (LSR II Fortessa, Apogee A50) were systematically outside the robust mean  $\pm$  robust SD range for both samples. In the specific case of Apogee A50, the discordance with expected values was clearly a result of an inappropriate choice of the set of beads (FSC instead of




**Fig. 1.** Inter-instrument variability of the platelet microparticle (PMP) ratio between samples. PMP counts of sample A were fixed at 100% and counts in sample B were displayed as a percentage of sample A for both groups of instruments, using side scatter (SSC) or forward scatter (FSC) as preferred parameter to define the MP gate of analysis.

SSC). Finally, the inter-laboratory variability of PMP counts was 37% and 28% for samples A and B, respectively (Fig. 2C), with mean and 95% confidence interval at 8490 (7190–9790) PMP/ $\mu$ L and 3075 (2745–3400) PMP/ $\mu$ L for samples A and B, respectively. Interestingly, we found no significant difference in PMP counts between instruments using SSC or FSC as the preferred trigger (sample A,  $8900 \pm 4000$  PMPs/ $\mu$ L vs.  $8000 \pm 2000$  PMPs/ $\mu$ L,  $P = 0.8$ ; sample B,  $3100 \pm 980$  PMPs/ $\mu$ L vs.  $2800 \pm 550$  PMP/ $\mu$ L,  $P = 0.5$ ). However, the inter-instrument variability was higher for SSC instruments compared with FSC-oriented instruments (sample A, 46% vs. 25%; sample B, 31% vs. 19%), probably because of a greater diversity of tested models.

## Discussion

This study is the first to demonstrate that standardization is possible for MP enumeration by flow cytometry. We also demonstrated that size-calibrated polystyrene beads can be used as a standardization tool for MP



**Fig. 2.** Inter-instrument variability of platelet microparticle (PMP) counts. (A and B) Platelet-derived microparticle counts determined as events/ $\mu$ L in sample A (A) or sample B (B) by each qualified flow cytometer using either side scatter (SSC) or forward scatter (FSC) as the preferred parameter. The grey area is defined by the robust mean ( $X^*$ )  $\pm$  the robust standard deviation ( $SD^*$ ).  $X^*$  and  $SD^*$  were calculated taking into account only results from cytometers with values between the median  $\pm$  SD. (C) Inter-instrument variability (CV) of PMP counts.  $P < 0.05$  was considered significant.

enumeration, provided that intrinsic instrument behaviors for size-related measurements have been taken into account. Bead-based strategies have been criticized because the relationship between bead and MP sizes is not obvious and highly depends on the size-related scatter parameter used and on the refractive index [13–16]. Therefore, the beads should not be used as calibrators to derive absolute size values for MPs. Other standards with refractive indices closer to those of MPs may be a better alternative. However, such a standardization strategy awaits similar multicenter validation. Moreover, whereas we focused in this study on the use of scatter for triggering MP analysis, several other groups focus on fluorescence as a preferred threshold [4,17–20]; however, thresholding on fluorescence currently encounters several practical limitations. Although generic labels have been proposed (e.g. lipophilic fluorescent labels such as PKH dyes), the labeling procedure of MPs in complex body fluids such as plasma is hardly applicable, necessitating protocols that use specialized laboratory equipment to get rid of free dye and prevent measurement of artifacts. Indeed, non-specific fluorescent background due to the staining of lipoprotein particles present in plasma, added to the variability in fluorescence sensitivity among instruments, remain two major limitations in defining any clear-cut, reproducible, fluorescent threshold level that could be generally applied. Most probably, both fluorescence and scatter triggering strategies will have to be combined.

In contrast to the previous ISTH standardization study [6], the proposed bead-based strategy is now applicable on most commercially available instruments. No significant variability was observed between instrument families measuring PMPs with different optical systems. These results open the way for multicenter studies comparing MP counts in clinical samples. Although only PMPs were measured in this workshop, it can be anticipated that the same strategy could be extended to other clinically-relevant MP subsets. However, this standardization strategy displays several limitations. (i) It still addresses only a small fraction of MPs, a large part being below the detection limit of instruments. (ii) Homogeneous re-treatment of raw data by the core laboratory was still required. Thus specific training is still needed for data treatment. (iii) It was mainly focused on harmonizing the scatter-based MP gates. Although the conditions of fluorescence detection were tentatively harmonized in this study using specifically designed Fluo-Setting-Beads to be set in similar target channels, the complete standardization of fluorescence measurements would require more sophisticated approaches [21]. (iv) The strategy has to be challenged using future instruments with different optical design.

Despite still having significant limitations, this study is the first to demonstrate a real potential for standardization of MP enumeration across different FCM platforms. Additional standardization efforts are mandatory to allow the evaluation of the clinical relevance of MP counts at a

multicenter level, and should accompany the continuous improvement in the sensitivity of instruments to detect progressively smaller MPs.

### Addendum

S. Cointe, C. Judicone, and S. Robert performed the research, collected the data and analyzed and interpreted the data. M. J. Mooberry and P. Poncelet designed the research and reviewed the manuscript. M. Wauben and R. Nieuwland reviewed the manuscript. N. S. Key and F. Dignat-George supervised the work and reviewed the manuscript. R. Lacroix designed the research, supervised the work, analyzed and interpreted the data and wrote the manuscript.

### Acknowledgements

The study was written on behalf of the ISTH SSC Workshop and the members are listed in the Appendix. This study received financial support from the International Society on Thrombosis and Haemostasis. Research reported in this publication was supported by the Office of the Director, National Institutes of Health under award number S10OD012052.

### Disclosure of Conflict of Interests

C. Judicone and P. Poncelet are full-time employees of BioCytex. For the workshop, BioCytex provided Megamix beads and non-commercial reagents including counting and fluo setting beads. Separate from this study, F. Dignat-George and R. Lacroix declare a collaboration contract with Stago (on fibrinolytic microparticles: licensed patent).

### Supporting Information

Additional Supporting Information may be found in the online version of this article:

**Fig. 1.** Platelet-derived microparticle counts in sample C.  
**Data S1.** Microparticle (MP) protocol settings.

### Appendix

#### ISTH SSC Workshop

A. Amirkhosravi, Orlando, FL, USA; J. Annichino-Bizzacchi, Campinas, Brazil; G. J. A. Arkesteijn, Utrecht, the Netherlands; M.-C. Bene, Nantes, France; N. Bailly, Yvoir, Belgium; A. Belkina, Boston, MA, USA; S. Biichle, Besançon, France; A. Boing, Amsterdam, the Netherlands; I. Bosch, Boston, MA, USA; T. Bouriche, Marseille, France; M. Brambilla, Milan, Italy; E.-L. Buzás, Budapest, Hungary; M. Camera, Milan, Italy; P. Canzano, Milan,

Italy; A. Carter, Liverpool, UK; W. Chandler, Houston, TX, USA; B. Chatelain, Yvoir, Belgium; D. Connor, Darlinghurst, Australia; M. Davila, Orlando, FL, USA; N. de Bosch, Caracas, Venezuela; A. Enjeti, Waratah, Australia; D. Faille, Paris, France; A. Falanga, Bergamo, Italy; M. Flores, Campinas, Brazil; F. Garnache Ottou, Besançon, France; K. Ghosh, Mumbai, India; A. Gruca, Krakow, Poland; J.-Y. Han, Busan, Korea; M. Harrison, Waterford, Ireland; P. Harrison, Birmingham, UK; P. Hidalgo, Santiago, Chile; D. Hirschkorn, San Francisco, CA, USA; J. Kappelmayr, Debrecen, Hungary; N. Key, Chapel Hill, NC, USA; M. Kollars, Vienna, Austria; J. Kraan, Rotterdam, the Netherlands; B. Kulkarni, Mumbai, India; H. Kwaan, Chicago, IL, USA; V. Latger-Cannard, Vandœuvre-les-Nancy, France; W. Li, Bronx, NY, USA; H. Louis, Vandœuvre-les-Nancy, France; L. Madden, Hull, UK; N. Matijević, Houston, TX, USA; F. Mobarrez, Stockholm, Sweden; M. Moobery, Chapel Hill, NC, USA; F. Mullier, Yvoir, Belgium; M. Nguyen-De Bernon, Paris, France; P. Norris, San Francisco, CA, USA; R. Otero, Victoria, Australia; E. Pallinger, Budapest, Hungary; R. Patils, Mumbai, India; J. Pereira, Santiago, Chile; K. Peter, Victoria, Australia; P. Poncelet, Marseille, France; L.-A. Ramon-Núñez, Valencia, Spain; C. Roumier, Lille, France; V. Sanchez, Seville, Spain; E. Seilles, Besançon, France; E. Stępień, Krakow, Poland; S. Susen, Lille, France; C. J. Tartari, Bergamo, Italy; V. Tintiller, Lille, France; M. van Schilf-gaarde, Amsterdam, the Netherlands; A. Vignoli, Bergamo, Italy; V. Vila, Valencia, Spain; H. Wallen, Houston, TX, USA; S. Watson, Birmingham, UK; M. Wauben, Utrecht, the Netherlands; I. Weiss, Chicago, IL, USA; X. Wu, Seattle, WA, USA; C. Yates, Birmingham, UK.

## References

- 1 Revenfeld AL, Baek R, Nielsen MH, Stensballe A, Varming K, Jorgensen M. Diagnostic and prognostic potential of extracellular vesicles in peripheral blood. *Clin Ther* 2014; **36**: 830–46.
- 2 van der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, Sturk A, van Leeuwen TG, Nieuwland R. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. *J Thromb Haemost* 2014; **12**: 1182–92.
- 3 Robert S, Lacroix R, Poncelet P, Harhour K, Bouriche T, Judicone C, Wischhusen J, Arnaud L, Dignat-George F. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles—brief report. *Arterioscler Thromb Vasc Biol* 2012; **32**: 1054–8.
- 4 Hoen EN, van der Vlist EJ, Aalberts M, Mertens HC, Bosch BJ, Bartelink W, Mastrobattista E, van Gaal EV, Stoorvogel W, Arksteijn GJ, Wauben MH. Quantitative and qualitative flow cytometric analysis of nanosized cell-derived membrane vesicles. *Nanomedicine*. 2011; **8**: 712–20.
- 5 Zhu S, Ma L, Wang S, Chen C, Zhang W, Yang L, Hang W, Nolan JP, Wu L, Yan X. Light-scattering detection below the level of single fluorescent molecules for high-resolution characterization of functional nanoparticles. *ACS Nano* 2014; **8**: 10998–1006.
- 6 Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. *J Thromb Haemost* 2010; **8**: 2571–4.
- 7 Robert S, Poncelet P, Lacroix R, Arnaud L, Giraud L, Hauchard A, Sampol J, Dignat-George F. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? *J Thromb Haemost* 2009; **7**: 190–7.
- 8 Poncelet P, Robert S, Bouriche T, Bez J, Lacroix R, Dignat-George F. Standardized counting of circulating platelet microparticles using currently available flow cytometers and scatter-based triggering: Forward or side scatter? *Cytometry A*. 2016; **89**: 148–58.
- 9 Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J, Dignat-George F. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. *J Thromb Haemost* 2012; **10**: 437–46.
- 10 Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. *J Thromb Haemost* 2013; **11**: 1190–3.
- 11 Bigos M. Separation index: an easy-to-use metric for evaluation of different configurations on the same flow cytometer. *Curr Protoc Cytom*. Hoboken NJ: Wiley J., 2007: Chapter 1: Unit1 21.1.21.1–1.21.6
- 12 Huber P. *Robust statistics*. Hoboken, NJ: Wiley, 1981.
- 13 Robert S, Poncelet P, Lacroix R, Raoult D, Dignat-George F. More on: calibration for the measurement of microparticles: value of calibrated polystyrene beads for flow cytometry-based sizing of biological microparticles. *J Thromb Haemost* 2011; **9**: 1676–8.
- 14 Mullier F, Bailly N, Chatelain C, Dogne JM, Chatelain B. More on: calibration for the measurement of microparticles: needs, interests, and limitations of calibrated polystyrene beads for flow cytometry-based quantification of biological microparticles. *J Thromb Haemost* 2011; **9**: 1679–81.
- 15 Konokhova AI, Yurkin MA, Moskalensky AE, Chernyshev AV, Tsvetovskaya GA, Chikova ED, Maltsev VP. Light-scattering flow cytometry for identification and characterization of blood microparticles. *J Biomed Opt* 2012; **17**: 057006.
- 16 Gardiner C, Shaw M, Hole P, Smith J, Tannetta D, Redman CW, Sargent IL. Measurement of refractive index by nanoparticle tracking analysis reveals heterogeneity in extracellular vesicles. *J Extracell Vesicles*. 2014; **3**: 25361.
- 17 Arraud N, Gounou C, Linares R, Brisson AR. A simple flow cytometry method improves the detection of phosphatidylserine-exposing extracellular vesicles. *J Thromb Haemost* 2015; **13**: 237–47.
- 18 Arraud N, Gounou C, Turpin D, Brisson AR. Fluorescence triggering: A general strategy for enumerating and phenotyping extracellular vesicles by flow cytometry. *Cytometry A*. 2016; **89**: 184–95.
- 19 Nolan JP. Flow Cytometry of extracellular vesicles: potential, pitfalls, and prospects. *Curr Protoc Cytom*. 2015; **73**: 13.4.1–6.
- 20 van der Vlist EJ, Nolte-t Hoen EN, Stoorvogel W, Arksteijn GJ, Wauben MH. Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. *Nat Protoc* 2012; **7**: 1311–26.
- 21 Stoner SA, Duggan E, Condello D, Guerrero A, Turk JR, Narayanan PK, Nolan JP. High sensitivity flow cytometry of membrane vesicles. *Cytometry A*. 2016; **89**: 196–206.